Story
Scribe Therapeutics Files for Nasdaq Initial Public Offering
Scribe Therapeutics, a biotechnology firm, has officially filed for an initial public offering (IPO), signaling its intent to become a publicly traded company on the Nasdaq Global Market. The company submitted a registration statement, proposing to trade under the ticker symbol SCTX.
Details of the Offering
According to the filing, the number of shares to be offered and the target price range for the IPO have not yet been determined. The registration statement included placeholder values for these figures, a common practice in preliminary filings. Currently, there is no public market for Scribe's common stock.
A consortium of investment banks is underwriting the proposed offering. The joint book-running managers listed in the filing are:
- Leerink Partners
- Goldman Sachs & Co. LLC
- Guggenheim Securities
- Wells Fargo Securities
AdPath to Going Public
The filing marks the first formal step in Scribe Therapeutics' process of going public, which will allow it to raise capital from public investors. The completion of the IPO is contingent upon the company meeting all of Nasdaq’s listing standards and broader market conditions.
For investors, this development places Scribe on the IPO pipeline, but key financial details needed for valuation will only become available in subsequent filings. The move indicates the company's strategy to fund future growth and research initiatives through equity markets.